The upregulation of PD‐L1 within tumor tissues facilitates the activation of the therapeutic effects of ICIs, including anti‐PD‐1/PD‐L1 monoclonal antibodies [20, 21], while the activation of PD‐L1 may also be a factor inducing tolerance to immunotherapy [22]. The gene discussed is PDCD1; the disease is neoplasm.